CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
Rezum Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02940392
NCT02940392N/ACompleted

Rezum First in Man Feasibility Study for the Treatment of BPH With the Rezum System

Boston Scientific Corporation·interventional·Posted Oct 20, 2016·Updated Mar 5, 2021

In Brief

A clinical study evaluating Rezum System for Benign Prostatic Hyperplasia and 6 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

Evaluate the effect of the NxThera BPH Rezum System on prostate tissue in subjects suffering from LUTS symptoms secondary to benign prostatic hyperplasia (BPH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesDominican Republic
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 20, 2016
Enrollment StartMar 19, 2012
Primary CompletionMay 19, 2017
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 9.7 years ago

Interventions

Rezum Systemdevice

The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate "wet" thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure.